The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs).
This report on the U.S. market for OTC GI products presents a description of upper gastrointestinal conditions and diseases, the OTC treatments available, and clinical and business trends affecting the market, consumer behavior and attitudes, and promotional activities in the sector. The report details OTC GI products addressing ailments such as stomach upset, diarrhea, ulcers, and heartburn (gastroesophageal reflux).
The report provides a comprehensive analysis of the GI products that are currently marketed and those that are likely to enter the market in future. The study focuses on the direction the market is moving and the factors that will fuel sustainable growth. Trends covered in the report include consumer usage of tablets and liquids, dual regulatory status, consumer interest in self-medication and the impact of direct-to-consumer advertising. The report also discusses the consumer behavior in the United States toward OTC GI drugs.
The report provides sales data and market share in information on a range of OTC GI products and forecasts sales to 2008, while outlining the key market factors and the expected future trends in each category. For the purposes of this study, OTC GI products have been categorized into the following six generic groups:
H2 Receptor Antagonists
Proton Pump Inhibitors (PPI)
The report also analyzes the industry as a whole, while exploring its relationship with various traditional healthcare delivery channels. The report also provides the profiles of key players operating in the market.